Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Cleansing Notice – Under Section 708A(5)(e) of the Corporations Act
08:56am, Friday, 06'th Mar 2026
Not for release to US wire service or distribution in the United States PERTH, Western Australia, March 06, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (O
Completion of Tranche 1 of Placement and Valuation Update
08:52am, Friday, 06'th Mar 2026
Not for release to US wire service or distribution in the United States PERTH, Western Australia, March 06, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (“Novo” or the “Company”) (ASX: NVO)
Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies
06:05am, Friday, 06'th Mar 2026
U.S. considers global AI chip export restrictions, impacting Nvidia and AMD as shares fall on regulatory risk. A 30-day U.S. waiver allows India to purchase stranded Russian crude, aiming to stabilize
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
05:07pm, Thursday, 05'th Mar 2026
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
04:05pm, Thursday, 05'th Mar 2026
Novo Nordisk's Kagrama showed less weight loss than Eli Lilly's Zepbound in a key 84-week trial. The setback could pressure Novo's obesity growth outlook until full data and strategy updates emerge.
First Look: Broadcom (AVGO) AI Beat; Tech Power Pledge
07:38am, Thursday, 05'th Mar 2026
Stock News Futures wobble as oil surges: U.S. stock futures edged lower while oil extended gains amid the Iran conflict, even as megacap tech like Nvidia (NVDA)
GLP-1 drugs protect against new or worsening addictions, large study shows
06:36pm, Wednesday, 04'th Mar 2026
Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance use disorders and alleviate existing addictions, according to findings from a large study of U.S. mil
Novo Nordisk Gets FDA Warning Over Ozempic Ad
12:16pm, Wednesday, 04'th Mar 2026
Novo Nordisk (NVO, Financials) has received a warning letter from the U.S. Food and Drug Administration over what regulators described as âfalse or misleading
US FDA warns Novo for second time about misleading Ozempic advertising
05:12pm, Tuesday, 03'rd Mar 2026
The U.S. Food and Drug Administration has told Novo Nordisk to stop running a consumer ad for its blockbuster diabetes drug Ozempic, saying the commercial makes false and misleadi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
04:25pm, Tuesday, 03'rd Mar 2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors ar
4 Factor Dividend Growth Strategy Remains Ahead Of Its Benchmark
10:11am, Tuesday, 03'rd Mar 2026
The 4-Factor Dividend Growth Portfolio, a rules-based alternative to SCHD, targets high-quality, growth-oriented dividend stocks using four equally weighted metrics. Since inception, the strategy has
Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early morning sell-off on Monday, the buy-the-dip buyers returned with a vengeance, and by the end of the Mo
Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk
07:13am, Tuesday, 03'rd Mar 2026
Novo Nordisk faces persistent valuation declines amid margin uncertainty, competitive pressures, and negative 2026 growth guidance. Despite margin compression risks, NVO remains a speculative contrari
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
01:26am, Tuesday, 03'rd Mar 2026
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told �
Novo Nordisk to Spend €432 Million Expanding Irish Wegovy Production
03:25pm, Monday, 02'nd Mar 2026
Novo Nordisk (NVO) is moving decisively to reinforce its manufacturing base, announcing a â¬432 million ($507 million) investment to upgrade and retrofit its A
